64 related articles for article (PubMed ID: 27163723)
1. Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor.
Kang G; Sohn BS; Pyo JS; Kim JY; Lee B; Kim KM
Mol Diagn Ther; 2016 Aug; 20(4):347-51. PubMed ID: 27178185
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of gastrointestinal stromal tumours.
Jakhetiya A; Garg PK; Prakash G; Sharma J; Pandey R; Pandey D
World J Gastrointest Surg; 2016 May; 8(5):345-52. PubMed ID: 27231512
[TBL] [Abstract][Full Text] [Related]
3. PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.
Baskin Y; Kocal GC; Kucukzeybek BB; Akbarpour M; Kayacik N; Sagol O; Ellidokuz H; Oztop I
Oncol Res; 2016; 24(1):41-53. PubMed ID: 27178821
[TBL] [Abstract][Full Text] [Related]
4. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P;
Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Falkenhorst J; Grunewald S; Mühlenberg T; Marino-Enriquez A; Reis AC; Corless C; Heinrich M; Treckmann J; Podleska LE; Schuler M; Fletcher JA; Bauer S
Oncotarget; 2016 Jul; 7(27):41390-41403. PubMed ID: 27167336
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?
Ramaswamy A; Ostwal V; Shetty O; Sahu A; Paul D; Pai T; Gurav M; Shetty N; Shrikhande S
J Gastrointest Cancer; 2016 Dec; 47(4):381-388. PubMed ID: 27217036
[TBL] [Abstract][Full Text] [Related]
7. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.
Schvartsman G; Wagner MJ; Zobniw CM; Trinh VA; Patel S; Somaiah N
Curr Oncol Rep; 2016 Aug; 18(8):49. PubMed ID: 27319943
[TBL] [Abstract][Full Text] [Related]
8. Targeting gastrointestinal stromal tumors: the role of regorafenib.
Schroeder B; Li Z; Cranmer LD; Jones RL; Pollack SM
Onco Targets Ther; 2016; 9():3009-16. PubMed ID: 27284251
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal Stromal Tumor: Genotype Frequency and Prognostic Relevance.
Kumari N; Priyaa V; Shukla P; Kumar A; Aggarwal R; Krishnani N
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):153-160. PubMed ID: 27258566
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Martin-Broto J; Hindi N
Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
[TBL] [Abstract][Full Text] [Related]
11. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
12. Current clinical management of gastrointestinal stromal tumor.
Akahoshi K; Oya M; Koga T; Shiratsuchi Y
World J Gastroenterol; 2018 Jul; 24(26):2806-2817. PubMed ID: 30018476
[TBL] [Abstract][Full Text] [Related]
13. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S
Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704
[TBL] [Abstract][Full Text] [Related]
14. Esterase-Responsive Polyglycerol-Based Nanogels for Intracellular Drug Delivery in Rare Gastrointestinal Stromal Tumors.
Schötz S; Griepe AK; Goerisch BB; Kortam S; Vainer YS; Dimde M; Koeppe H; Wedepohl S; Quaas E; Achazi K; Schroeder A; Haag R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004483
[TBL] [Abstract][Full Text] [Related]
15. BLU-285-the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor.
Schneider-Stock R
Ann Transl Med; 2018 Jun; 6(11):232. PubMed ID: 30023395
[No Abstract] [Full Text] [Related]
16. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments.
Pogorzelski M; Falkenhorst J; Bauer S
Curr Opin Oncol; 2016 Jul; 28(4):331-7. PubMed ID: 27163723
[TBL] [Abstract][Full Text] [Related]
17. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic agents in gastrointestinal stromal tumours.
Falkenhorst J; Hamacher R; Bauer S
Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
[TBL] [Abstract][Full Text] [Related]
19. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
